Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.
Rankin BD, Sood S, Park YJ, Rimke A, Abduelmula A, Georgakopoulos JR, Maliyar K, Leung F, Stark LA, Devani AR, Yeung J, Prajapati VH. Rankin BD, et al. Among authors: rimke a. Dermatitis. 2024 Oct 24. doi: 10.1089/derm.2024.0208. Online ahead of print. Dermatitis. 2024. PMID: 39446652 No abstract available.
Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.
Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Devani AR, Vender R, Yeung J, Prajapati VH. Sood S, et al. Among authors: rimke a. J Am Acad Dermatol. 2024 Dec;91(6):1265-1267. doi: 10.1016/j.jaad.2024.07.1515. Epub 2024 Aug 23. J Am Acad Dermatol. 2024. PMID: 39182686 Free article. No abstract available.
Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective Review.
Rankin BD, Sood S, Park YJ, Rimke A, Abduelmula A, Georgakopoulos JR, Leung F, Stark LA, Devani AR, Yeung J, Prajapati VH. Rankin BD, et al. Among authors: rimke a. Dermatitis. 2024 Jun 24. doi: 10.1089/derm.2024.0097. Online ahead of print. Dermatitis. 2024. PMID: 38913326 No abstract available.
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
Sood S, Rimke A, Rankin BD, Abduelmula A, Georgakopoulos JR, Maliyar K, Bagit A, Leung F, Stark LA, Devani AR, Vender R, Yeung J, Prajapati VH. Sood S, et al. Among authors: rimke a. J Am Acad Dermatol. 2024 Nov;91(5):936-939. doi: 10.1016/j.jaad.2024.05.085. Epub 2024 Jun 15. J Am Acad Dermatol. 2024. PMID: 38885841 No abstract available.
Real-world effectiveness and safety of upadacitinib for the treatment of atopic dermatitis in adult patients switched from dupilumab: A multicenter retrospective study.
Georgakopoulos JR, Sheka D, Rankin B, Maliyar K, Rimke A, Prajapati VH, Yeung J. Georgakopoulos JR, et al. Among authors: rimke a. J Am Acad Dermatol. 2023 Dec;89(6):1308-1311. doi: 10.1016/j.jaad.2023.08.059. Epub 2023 Aug 28. J Am Acad Dermatol. 2023. PMID: 37648068 No abstract available.
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class.
Bagit A, Maliyar K, Georgakopoulos JR, Rankin B, Rimke A, Mufti A, Le H, Vender R, Prajapati VH, Yeung J. Bagit A, et al. Among authors: rimke a. JAAD Int. 2023 May 26;12:136-138. doi: 10.1016/j.jdin.2023.05.006. eCollection 2023 Sep. JAAD Int. 2023. PMID: 37409313 Free PMC article. No abstract available.
12 results